此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Edwards PASCAL 经导管瓣膜修复系统关键临床试验 (CLASP II TR)

2026年11月13日 更新者:Edwards Lifesciences

一项前瞻性、多中心、随机、对照的关键试验,旨在评估使用 Edwards PASCAL 经导管瓣膜修复系统和最佳药物治疗 (OMT) 进行经导管三尖瓣修复术与单独使用 OMT 治疗三尖瓣返流患者的安全性和有效性

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

研究概览

地位

主动,不招人

条件

干预/治疗

详细说明

A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. Patients will be seen for follow-up visits at discharge, 30 days, 3 months, 6 months, and annually through 5 years.

研究类型

介入性

注册 (估计的)

1270

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Vancouver、British Columbia、加拿大、V6Z 1Y6
        • St. Paul's Hospital
    • Ontario
      • Hamilton、Ontario、加拿大、L8L 2X2
        • Hamilton Health Services
      • Ottawa、Ontario、加拿大、K1Y 4Q7
        • University of Ottawa Heart Institute
      • Toronto、Ontario、加拿大、M4N 3M5
        • Sunnybrook Health Sciences Centre
      • Toronto、Ontario、加拿大、M5B 1W8
        • St. Michael's Hospital
    • Quebec
      • Québec、Quebec、加拿大、G1V 4G5
        • Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
    • Arizona
      • Phoenix、Arizona、美国、85006
        • Banner University Medical Center Phoenix
      • Tucson、Arizona、美国、85712
        • Tucson Medical Center Healthcare
    • California
      • Irvine、California、美国、92868
        • University of California, Irvine
      • La Jolla、California、美国、92037
        • SCPMG - Kaiser San Diego
      • Los Angeles、California、美国、90048
        • Cedars Sinai Medical Center
      • Los Angeles、California、美国、90095
        • UCLA Medical Center
      • San Francisco、California、美国、94143
        • University of California, San Francisco
      • San Francisco、California、美国、94118
        • Kaiser Permanente San Francisco
      • Stanford、California、美国、94305
        • Stanford University
    • Colorado
      • Denver、Colorado、美国、80218
        • St. Joseph Hospital
      • Loveland、Colorado、美国、80538
        • Medical Center of the Rockies
    • Florida
      • Gainesville、Florida、美国、32605
        • The Cardiac and Vascular Institute Research Foundation
      • Miami Beach、Florida、美国、33140
        • Mount Sinai Medical Center
      • Naples、Florida、美国、34102
        • NCH Healthcare System
      • Sarasota、Florida、美国、34239
        • Sarasota Memorial Health Care System
      • Tallahassee、Florida、美国、32308
        • Tallahassee Research Institute
    • Georgia
      • Atlanta、Georgia、美国、30309
        • Piedmont Healthcare, Inc.
      • Atlanta、Georgia、美国、30308
        • Emory University Hospital Midtown / Emory University - St. Joseph's Hospital
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University
    • Indiana
      • Indianapolis、Indiana、美国、46290
        • Ascension St. Vincent Heart Center Cardiovascular Research Institute
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa Hospitals & Clinics
    • Louisiana
      • New Orleans、Louisiana、美国、70121
        • Ochsner Medical Center
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan
      • Detroit、Michigan、美国、48202
        • Henry Ford Hospital
      • Royal Oak、Michigan、美国、48073
        • William Beaumont Hospital - Royal Oak
      • Saginaw、Michigan、美国、48601
        • St. Mary's of Ascension Research
    • Minnesota
      • Maplewood、Minnesota、美国、55109
        • Fairview Health Services
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • Missouri
      • Kansas City、Missouri、美国、64111
        • Saint Luke's Hospital of Kansas City
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • Montana
      • Missoula、Montana、美国、59802
        • Providence St. Patrick Hospital
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Camden、New Jersey、美国、09103
        • Cooper Health Systems
      • Morristown、New Jersey、美国、07962
        • Morristown Medical Center
      • New Brunswick、New Jersey、美国、08901
        • Rutgers Robert Wood Johnson Medical School
    • New York
      • Buffalo、New York、美国、14203
        • State University of New York at Buffalo
      • New York、New York、美国、10065
        • Weill Cornell Medicine
      • New York、New York、美国、10032
        • Columbia University Irving Medical Center/NYPH
      • New York、New York、美国、10075
        • Lenox Hill Hospital, Northwell Health /Northshore University Hospital Manhasset
      • Rochester、New York、美国、14621
        • Rochester General Hospital
      • Roslyn、New York、美国、11576
        • St. Francis Hospital
      • The Bronx、New York、美国、10467
        • Montefiore Medical Center / Arts Pavilion / Hutchinson Metro Center Clinic / Weiler Hospital / Moses Hospital
    • North Carolina
      • Chapel Hill、North Carolina、美国、27517
        • University of North Carolina
    • North Dakota
      • Fargo、North Dakota、美国、58104
        • Sanford Medical Center Fargo
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • The Christ Hospital
      • Cincinnati、Ohio、美国、45242
        • TriHealth-Bethesda North Hospital
      • Columbus、Ohio、美国、43210
        • The Ohio State University
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73112
        • Integris Baptist Medical Center
      • Oklahoma City、Oklahoma、美国、73120
        • Oklahoma Cardiovascular Research Group
      • Tulsa、Oklahoma、美国、74104
        • Oklahoma Heart Institute at Hillcrest Medical Center
    • Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health & Science University
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033
        • Penn State Hershey
      • Philadelphia、Pennsylvania、美国、19104
        • Pennsylvania Presbyterian Medical Center / Hospital of the University of Pennsylvania
      • Wormleysburg、Pennsylvania、美国、17043
        • Pinnacle Health Cardiovascular Institute/UPMC Pinnacle
      • Wynnewood、Pennsylvania、美国、19096
        • Lankenau Heart Institute
    • South Carolina
      • Charleston、South Carolina、美国、29245
        • Medical University of South Carolina
    • Tennessee
      • Chattanooga、Tennessee、美国、37403
        • Erlanger Health System
      • Nashville、Tennessee、美国、37212
        • Vanderbilt University Medical Center
    • Texas
      • Houston、Texas、美国、77030
        • The University of Texas Health Science Center at Houston
      • Houston、Texas、美国、77004
        • HCA Houston Healthcare Medical Center
      • Houston、Texas、美国、77030
        • Baylor College of Medicine St. Luke's Medical Center
      • Houston、Texas、美国、77030
        • UTHealth/Memorial Hermann Hospital
      • Plano、Texas、美国、75093
        • Baylor Scott & White - The Heart Hospital - Plano
    • Utah
      • Murray、Utah、美国、84107
        • Intermountain Medical Center
      • St. George、Utah、美国、84790
        • St. George Regional Hospital
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia Health System
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University
      • Roanoke、Virginia、美国、24014
        • Carilion Medical Center
    • Washington
      • Seattle、Washington、美国、98101
        • Virginia Mason Medical Center
      • Seattle、Washington、美国、98122
        • Swedish Medical Center
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • Medical College of Wisconsin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Eighteen (18) years of age or older
  • Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
  • Severe or greater tricuspid regurgitation
  • New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
  • Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
  • Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements

Exclusion Criteria:

  • Tricuspid valve anatomy not evaluable by TTE or TEE

  • Tricuspid valve anatomy precludes proper device deployment and function

  • Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)

  • Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following:

    1. Would prevent proper TR reduction due to interaction of the lead with the leaflets
    2. Were implanted in the RV within the last 90 days prior to the point of enrollment
  • Primary non-degenerative tricuspid disease

  • Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL

  • Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction

  • Significant intra-cardiac mass, thrombus, or vegetation per echo core lab assessment

  • Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 90 days

  • Recent Stroke

  • Active gastrointestinal (GI) bleeding

  • Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV

  • Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days

  • Any of the following cardiovascular procedures:

    1. Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days prior to the point of enrollment
    2. Carotid surgery within 30 days prior to the point of enrollment
    3. Direct current cardioversion within the last 30 days prior to the point of enrollment
    4. Leadless RV pacemaker implant within the last 30 days prior to the point of enrollment
    5. Cardiac surgery within 90 days prior to the point of enrollment
  • Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation

  • Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid stenosis

  • Active endocarditis within the last 90 days or infection requiring antibiotic therapy within the last 14 days

  • Patient is oxygen-dependent or requires continuous home oxygen

  • Pregnant, breastfeeding, or planning pregnancy within the next 12 months (365 days)

  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator

  • Patient is currently participating in another investigational biologic, drug, or device clinical study

  • Patient has other medical, social, or psychological conditions that preclude appropriate consent and follow-up, or the patient is under guardianship

  • Any patient considered to be vulnerable

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Edwards PASCAL System & OMT

Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation

Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy

其他名称:
  • 经导管三尖瓣修复术 (TTVr)

Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT

Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation

有源比较器:Optimal Medical Therapy (OMT)

Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation

Optimal Medical Therapy alone in patients with tricuspid regurgitation

实验性的:Single-Arm Registry

Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization

Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy

其他名称:
  • 经导管三尖瓣修复术 (TTVr)

Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT

Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation

实验性的:Continued Access Study

Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation

Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy

其他名称:
  • 经导管三尖瓣修复术 (TTVr)

Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT

Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, and Quality of Life improvement (measured by KCCQ score)
大体时间:6 months

Comparison of number of participants with composite endpoint events between experimental and active comparator arms

6 months

次要结果测量

结果测量
措施说明
大体时间
1 Grade Reduction in TR Severity
大体时间:6, 12 months

Total number of participants with at least 1 grade reduction in TR severity

6, 12 months
Quality of Life (QOL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
大体时间:3, 6, and 12 months

Change in KCCQ score from baseline

3, 6, and 12 months
All Cause Mortality
大体时间:12 months, 24 months

Total number of deaths from any cause

12 months, 24 months
Death and Heart Failure Hospitalizations
大体时间:12 months

Total number of deaths and hospital admissions due to heart failure

12 months
All-cause Mortality, TV Surgery or TV Interventions
大体时间:24 months

Total number of deaths, TV surgeries or interventions

24 months
Right ventricular end-diastolic diameter (RVEDD mid)
大体时间:12 months

Change in right ventricular end-diastolic diameter (RVEDD mid)

12 months
Major Adverse Events (MAEs)
大体时间:30 days

Overall rate of Major Adverse Events (MAEs)

30 days
Reduction in TR grade
大体时间:Intraprocedural post-implantation

Reduction in TR severity as assessed by TEE pre- and post-implantation

Intraprocedural post-implantation
All-Cause Mortality
大体时间:12 months, annually through 5 years

Total number of deaths from any cause

12 months, annually through 5 years
Heart failure hospitalizations
大体时间:12 months, annually through 5 years

Total number of hospital admissions due to heart failure

12 months, annually through 5 years
Non-elective tricuspid valve re-intervenitions (percutaneous or surgical)
大体时间:12 months, annually through 5 years

Total number of non-elective tricuspid valve re-interventions

12 months, annually through 5 years
Durable RVAD implantation or heart transplant
大体时间:12 months, annually through 5 years

Total number of patients requiring RVAD impantantion or heart transplant

12 months, annually through 5 years
Need for paracentesis
大体时间:12 months, annually through 5 years

Total nunber of patients who required paracentesis

12 months, annually through 5 years
All cause mortality or the first heart failure hospitalization for patients with massive or torrential TR at baseline
大体时间:12, 24 months

Time to death or first heart failure hospitalization

12, 24 months
All-cause Hospitalizations
大体时间:12 months

Number of hospitalizations for any cause

12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Martin B. Leon, MD、Columbia University
  • 首席研究员:Michael J. Mack, MD、Baylor Scott and White Health
  • 学习椅:Gorav Ailawadi, MD、University of Michigan
  • 首席研究员:Charles Davidson, MD、Northwestern University
  • 学习椅:Allen Anderson, MD、The University of Texas Health Science Center at San Antonio

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年12月11日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2031年12月31日

研究注册日期

首次提交

2019年9月18日

首先提交符合 QC 标准的

2019年9月18日

首次发布 (实际的)

2019年9月20日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2019-07

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.